Methamphetamines clinical trials at University of California Health
5 in progress, 3 open to eligible people
Expression of Stress Markers During Meth Treatment (EXPRESS+)
open to eligible males ages 18-45
This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use disorder.
at UCLA
Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV
open to eligible people ages 18-69
The goal of this clinical trial is to learn whether it is possible to use intramuscular (IM) ketamine in combination with psychotherapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in publicly insured patients with or at-risk for HIV disease. The main questions it aims to answer are: - Do publicly insured patients find ketamine-assisted psychotherapy feasible and acceptable as a potential treatment for MeUD? - Is IM ketamine safe and tolerable among patients with MeUD? Participants will: - Receive 3 monitored doses of IM ketamine - Have 3 preparation and 4 integration psychotherapy visits - Report their daily amounts of methamphetamine used prior to, during, and up to 3 months following the intervention
at UCSF
Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
open to eligible people ages 18-65
The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.
at UCLA UCSD
CHAMPION: Combining HIV And Meth Prevention and Treatment Interventions Optimized for HIV-Negative MSM
Sorry, not yet accepting patients
The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: - To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. - To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.
at UCSD UCSF
Inflammation in Methamphetamine and STIs (IMSTI)
Sorry, in progress, not accepting new patients
This clinical trial aims to investigate the effects of a decline in methamphetamine use on rectal inflammatory cytokine levels, substance use contexts, and HIV/STI risk behavior. This clinical trial also seeks to evaluate joint effects of methamphetamine use and rectal gonorrhea/chlamydia infection on rectal inflammatory cytokine levels. The proposed trial will consist of 40 MSM, half with rectal gonorrhea/chlamydia infection at enrollment (n=20), with methamphetamine use disorder that will receive contingency management for methamphetamine reduction. Following baseline measurement, participants will be observed over the course of 8 weeks, where participants will complete behavioral surveys, provide urine for drug testing, and rectal samples for measurement of rectal inflammatory cytokine levels.
at UCLA
Our lead scientists for Methamphetamines research studies include Nicky Mehtani, MD MPH Michael J Li, PhD.
Last updated: